<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048541</url>
  </required_header>
  <id_info>
    <org_study_id>CP061CC</org_study_id>
    <nct_id>NCT01048541</nct_id>
  </id_info>
  <brief_title>Bladder Scan of Residual Urine With New Catheter</brief_title>
  <official_title>A Non-Inferiority Bladder Scan Study to Investigate Residual Urine After Use of Intermittent Catheters in Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male intermittent catheters (ICs) range from 340-500 mm long, with the European standard
      minimum length being 360 mm for a catheter without a balloon and 275 mm for one with a
      balloon. This length is defined by hospital standards although it is known that the male
      urethra has an approximate maximum length of 29 cmA new intermittent catheter developed by
      Coloplast A/S is a 30-cm-long sterile, ready-to-use, hydrophilic-coated male catheter. There
      is a lack of clinical data documenting that male ICs that are shorter and more or less
      flexible than standard catheters can sufficiently empty the bladder of male subjects. This
      will be tested using ultrasound to measure residual urine in the bladder following
      catheterisation with new product and standard length catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Residual Urine Volume</measure>
    <time_frame>3 catheterisations on 1 day</time_frame>
    <description>Residual urine was mesured by ultrasound measurement of bladder content after intermittent catherisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Difference in Incidence of Adverse Events (AEs) and Adverse Device Events (ADEs)</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Absolute RU Volume</measure>
    <time_frame>3 catheterisations on 1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>SpeediCath catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Catheter - SpeediCath Compact Male</intervention_name>
    <description>Compact catheter for intermittent catheterisation</description>
    <arm_group_label>Test product</arm_group_label>
    <other_name>SpeediCath</other_name>
    <other_name>Test catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpeediCath</intervention_name>
    <description>Catheter for intermittent catheterisation</description>
    <arm_group_label>SpeediCath catheter</arm_group_label>
    <other_name>Test catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a male IC user able to self-catheterise

          2. Subject has used hydrophilic-coated ICs for at least 1 month

          3. Subject is at least 18 years old.

          4. Subject has provided informed consent.

        Exclusion Criteria:

          1. Subject has symptoms of UTI (ie, fever, autonomic dysreflexia, spasticity, discomfort
             or pain over the kidney or bladder, onset/increase in incontinence episodes, cloudy
             urine with increased odour, malaise, lethargy, or sense of unease).

          2. Subject has known abnormalities in the lower urinary tract.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burkhard Domurath, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Werner−Wicker−Klinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik S Knoth, M.Sc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Werner−Wicker−Klinik, Abteilung für Neuro−Urologie</name>
      <address>
        <city>Bad Wildungen</city>
        <state>Hessen</state>
        <zip>34537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>January 9, 2012</results_first_submitted>
  <results_first_submitted_qc>August 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2012</results_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AB: First Test Catheter Then Standard Catheter</title>
          <description>Test catheter (SpeediCath Compact Male)used in the first period and Standard catheter (SpediCath straight) used in the second period</description>
        </group>
        <group group_id="P2">
          <title>BA: First Standard Catheter Then Test Catheter</title>
          <description>Standard catheter (SpediCath straight)used in the first period and test catheter (SpeediCath Compact Male) used in the second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study</title>
          <description>Includes groups randomized to standard catheter first and test catheter first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Residual Urine Volume</title>
        <description>Residual urine was mesured by ultrasound measurement of bladder content after intermittent catherisation</description>
        <time_frame>3 catheterisations on 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Catheter</title>
            <description>Test catheter (SpeediCath Compact Male)</description>
          </group>
          <group group_id="O2">
            <title>Standard Catheter</title>
            <description>Standard catheter (SpediCath straight)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residual Urine Volume</title>
          <description>Residual urine was mesured by ultrasound measurement of bladder content after intermittent catherisation</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="15.7"/>
                    <measurement group_id="O2" value="9.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference in Incidence of Adverse Events (AEs) and Adverse Device Events (ADEs)</title>
        <time_frame>Study period</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Absolute RU Volume</title>
        <time_frame>3 catheterisations on 1 day</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Catheter</title>
          <description>Test catheter (SpeediCath Compact Male)</description>
        </group>
        <group group_id="E2">
          <title>Standard Catheter</title>
          <description>Standard catheter (SpediCath straight)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Burning in the urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristine Gjødsbøl, PhD</name_or_title>
      <organization>Coloplast</organization>
      <phone>+4549113557</phone>
      <email>dkkg@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

